FuRyu has announced Beyblade X: EVOBATTLE, a follow-up to 2024’s Beyblade X: XONE, for Switch and PC (Steam). It will launch on November 13. In Japan, the physical edition for Switch will be priced at ...

The article details the celestial configuration of the waning Moon and Regulus in the constellation Leo for observation on October 15. Regulus is identified as a magnitude 1.4, quadruple-star system, ...

TOLEDO, Ohio — If you’re an early riser (or willing to become one), the morning of Saturday, Sept. 20, promises one of the best naked-eye sky events of the year: a slim crescent moon, the brilliant ...

Venus loomed bright in the sky early Friday morning, but if you missed it, you'll get another chance if you're an early riser tomorrow. Venus appeared in a conjunction with the moon and the star ...

On a specified date, the Moon will pass 0.8° north of Venus and 1.3° north of Regulus (magnitude 1.4), with Venus and Regulus separated by less than 0.5°. This celestial trio will rise around 4:30 A.M ...

One of the best naked-eye stargazing sights of the year is on offer to skywatchers this week — if you can rise before the sun Friday (Sept. 19). Just before sunrise, the crescent moon, the brilliant ...

The moon-planet-star trio are among the brightest objects in our solar system, meaning the impending conjunction should be incredibly easy to spot. A conjunction is an astronomical event in which at ...

Inspired by the anime and toys, Beyblade X-Battles has fast-paced, customizable spinning tops with special Xtreme Dash mechanics, allowing you to boost your Beyblade's speed, perform unanticipated ...

Will Somerindyke founded a military supply chain and logistics company called Regulus Global a decade ago. Now, he’s raising hundreds of millions for a new defense tech play — and Regulus is the first ...

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common ...

Novartis’ $1.7 billion Regulus Therapeutics buyout last month came after a hard-fought battle in which the Swiss pharma and another interested party raised the stakes several times, a new securities ...